The 5th Annual Innovators in Urology took place this year in Amsterdam, The Netherlands under the chairmanship of Professor Frans Debruyne, from the University Hospital Nijmegen, The Netherlands. A total of 46 delegates from 18 countries were invited to attend the meeting and disciplines included urology, radiotherapy and medical oncology. The focus of the meeting was the development of poster content and presentation, publication review techniques and conducting debates on prostate cancer screening and the use of prostate-specific antigen (PSA) as a surrogate end point for survival. In addition, keynote presentations were made by guest speakers on evolving imaging techniques in urological disease and the use of mouse models for human disease. Summarised below is a selection of the research topics presented. All research abstracts will be published in full in Prostate Cancer and Prostatic Diseases later this year.
Prostate cancer detection and prognosis
The clinical utility of identifying the DD3PCA3 prostate cancer gene marker in urine samples was the focus of one research group (Dr Peter Mulders, The Netherlands). Transcripts of the gene were quantitatively identified in urine sediments after prostatic massage in a group of 108 men who had undergone prostate biopsy based on a PSA level of 43 ng/ml. Control prostate cancer tissue showed a 66-fold upregulation of DD3PCA3 compared with benign prostate tissue. On biopsy, 24 men were shown to have prostate cancer and of these, 16 had positive urine samples for DD3PCA3, indicating an assay sensitivity of 67%. The negative predictive value was calculated as 88%.
Different methods of anaesthesia during transrectal prostate biopsy have been studied (Dr Can Ö bek, Turkey) . Comparative groups consisted of:
Group 1: control, no anaesthesia, Group 2: periprostatic nerve infiltration with 2% lidocaine (2.5 ml to either side of the prostate), Group 3: periprostatic nerve infiltration with 2% lidocaine plus perianal/intrarectal application of 2% lidocaine jelly (10 ml), Group 4: intravenous infusion of tramadol HCl at a dose of 1.5 mg/kg/100 ml saline.
A total of 75 patients in each group underwent 12 core biopsies. Median pain scores were 4.74 in controls, 2.60 in group 2, 2.12 in group 3 and 3.09 in group 4. Complication rates in each group were similar. Pathological aspects of solitary lymph node metastasis were studied with regard to treatment outcome in 97 patients who underwent pelvic lymph node dissection for prostate cancer between 1983 and 2001 in a retrospective analysis (Dr Mark-Oliver Grimm, Germany). Histologic sections of solitary lymph node metastasis were re-evaluated with regard to diameter, capsular penetration, stromal infiltration and location of the metastatic lesion. A total of 88 cases were confirmed as solitary lesions, and 51 of these appeared to be true micrometastases with a diameter of up to 2 mm; 25% were sized at less than 1 mm in diameter. Gross infiltration of the lymph node was recorded in 43 (49%) of cases and capsular penetration in 38 (43%). The 5-and 10-y tumour-specific survival of patients undergoing radical prostatectomy (n ¼ 81) was 94 and 51% compared with 50 and 17% for those receiving androgen deprivation therapy (n ¼ 7). Of the histological parameters analysed, only diameter of the lymph node deposit predicted tumour-specific outcome. Mean tumour-specific survival of patients with micrometastasis was 123 months compared with 98 months for larger ones (P ¼ 0.005).
Elevated serum HER-2/neu levels were reported as being associated with advancing prostate cancer stage, with overexpression noted in up to 85% of hormone refractory prostate cancer (Dr Samir Taneja, USA). Serum samples from 259 men who presented to a US clinic with prostate cancer or elevated serum PSA were tested for HER-2/neu protein using an ELISA-based quantitative serum assay. Results indicated higher mean levels in patients with hormone refractory prostate cancer (n ¼ 24; 13.56 ng/ml (range: 7.4-21.9)) than benign disease (n ¼ 33; mean 10.48 ng/ml (range: 7.6-13.9)) (P ¼ 0.0003) or localised prostate cancer regardless of grade (n ¼ 64; 11.34 ng/ml (range: 7.1-19.8)) (P ¼ 0.004). There was a trend for increasing Her-2/neu levels with increasing cancer stage. No elevation of level was observed in men receiving hormonal ablative therapy without evidence of recurrence. Validation of these results with tissue staining might allow the selection of a subset of patients who could benefit from HER-2/neu-directed therapy.
Results were presented from a study that tested the hypothesis that PSA values between 2 and 9 ng/ml at diagnosis were unrelated to different rates of biochemical disease recurrence (Dr Pierre Karakiewicz, Canada). A total of 4187 patients treated with radical prostatectomy between 1983 and 2000 were included in the study. Of these, complete data were collected from 3045 on pretreatment PSA, clinical stage, primary and secondary biopsy and Gleason grade. Cox models were used to determine the risk of recurrence following surgery in 1756 men with a pretreatment PSA of 2-9 ng/ml. Overall, 184 biochemical recurrences were recorded and six treatment failures were defined based on intraoperative diagnosis of nodal metastasis. Serum PSA was identified as an important predictor of treatment failure after accounting for primary and secondary Gleason grades and clinical stage. The rate of biochemical recurrence increased by a value of 1.53 for each ng/ ml of PSA in men with pretreatment values of 2-9 ng/ml. Freedom from recurrence at 5 y was estimated at 89% for a PSA of 2 ng/ml compared with 69% for a PSA of 9 ng/ml. These data have important implications for treatment decisions.
Prostate cancer therapy: present and future
The timing of testosterone rise following cessation of gonadotrophin releasing hormone (GnRH) analogue therapy was studied in 126 patients with rising PSA following definitive local treatment (Dr James Gulley, USA). After 6 months of a GnRH analogue alone (leuprolide or goserelin), patients received either thalidomide 200 mg/day or placebo. When PSA rose to 0.5 ng/ ml or baseline (whichever was lower), hormonal therapy was recommenced for a period of 6 months as long as there was no radiographic evidence of disease. Patients then switched over to the opposite oral treatment. Testosterone was measured at 3-month intervals while on hormonal therapy and at 1-month intervals on oral study drug. Data from 80 patients who completed an initial 6 months of GnRH were evaluated. Two factors were associated with a longer time to rise of testosterone to normal levels: age 467 y and low baseline testosterone levels (50-211 ng/dl). The median time to normal testosterone levels in patients aged 49-66 y was 27.7 weeks compared with 29.7 weeks in patients aged 466 y (P ¼ 0.08). The median time to rise in testosterone to 211 ng/dl or higher in 56 patients with normal baseline testosterone levels was 28 weeks. In contrast, none of the five patients with low baseline testosterone rose to this level.
The cytoreductive efficacy of bicalutamide 150 mg or goserelin has been compared with no hormonal manipulation in prostate cancer patients prior to brachytherapy (Mr Stephen Langley, UK). Hormonal therapy given prior to brachytherapy resulted in an 8% reduction in prostate volume in patients on bicalutamide and a 26% reduction in patients on goserelin. There was an 8% increase in volume in the placebo-treated patients. Although the luteinising hormone-releasing hormone analogue goserelin appears to be superior in decreasing prostate volume than the antiandrogen bicalutamide, the study was not randomised, and the fact that differences may be due to different populations and not a treatment effect cannot be discounted.
A study was reported examining the effect of phytooestrogens on cell growth and apoptosis in two prostate epithelial cell lines: PWR-1E (benign) and PC-3 (metastatic) (Dr Colm Morrissey, Ireland). Two phyto-oestrogens, apigenin and silybinin, significantly reduced cell numbers in both cell lines (Table 1) . Apigenin induced apoptosis in both cell lines while silybinin induced apoptosis in PWR-1E cells and cell cycle arrest in PC-3 cells. Further evidence suggested that the apoptotic process induced in PWR-1E cells was caspase dependent. The differential response in PC-3 cells might indicate that these cells were more resistant to the caspase-activated cell death pathway. These results suggest the importance of determining tumour phenotypes in the context of optimising treatment strategies.
A phase II study of the antisense oligonucleotide G3139, which is complimentary to the proto-oncogene bcl-2, in combination with docetaxel has been conducted by researchers in Canada (Dr Kim Chi, Canada). A total of 31 men with metastatic hormone refractory prostate cancer were included in the trial. A single cycle consisted of G3139 7 mg/kg/day on days 1-8 plus docetaxel 75 mg/m 2 i.v. on day 6, every 21 days. A median of four cycles (range 1-10) of treatment has been given to date. Partial response was achieved in four of 15 patients with measurable disease. A reduction in PSA of over 50% was reported in 15 of 31 patients. The most common grade 1-2 adverse events were fatigue (35%) and non-neutroWhat's hot in the prostate? M Gleave and CP Evans penic fever (31%). Grade 3-4 neutropenia occurred in 13 of 31 patients and in 27/146 cycles (18%); five patients had febrile neutropenia. Grade 3 fatigue was reported in three patients. It was concluded that the combination of G3139 plus docetaxel produced an encouraging PSA response and was well tolerated.
The efficacy of the COX-2 inhibitor celecoxib has been tested in 12 patients with biochemical relapse after definitive radiation therapy or radical prostatectomy (Dr Raj Pruthi, USA). PSA levels were measured at 3, 6 and 12 months. An inhibitory effect on PSA level was reported in 11 patients after 3 months of therapy. Three patients demonstrated a dramatic increase in their PSA doubling time of 3.1-fold over pretreatment values. There was also a significant shift of patients with rapid doubling times towards slower doubling times or even stable/declining PSA values up to 12 months of therapy (P ¼ 0.008). Ongoing studies are examining these effects in a larger patient cohort.
Prostate cancer: molecular biology and mechanisms
The invasive characteristics of malignant prostate epithelial cells has been studied in an in vitro invasion chamber model (Dr Ian McIntyre, UK). Results showed that the migration of the malignant prostate cancer cell line PC-3 was induced by bone marrow endothelium, bone marrow stroma and their extracellular matrixes. In contrast, the nonmalignant cell line PNT2-C2 demonstrated no such invasive ability. Primary BPH and prostate cancer cells were also studied for invasion potential. The former showed no capacity for invasion, whereas the prostate cancer cells invaded preferentially towards bone marrow stroma and prostatic fibroblasts. Confocal microscopy revealed that 80% of PC3 cells were bound within 60 min following invasion through a bone marrow endothelial cell layer and that all cells were bound by 90 min.
Hypoxia-induced resistance to cytotoxic chemotherapy has been studied in prostate cancer cell lines and shown to be inhibited by low concentrations of glyceryl trinitrate (GTN) (Dr Robert Siemens, Canada). Human PC-3 mouse TRAMP-C2 prostatic adenocarcinoma cells were incubated in 20% oxygen or 0.5% oxygen for 12 h in the presence or absence of 0.1 nM GTN. This was followed with incubation with doxorubicin for 1 h and then assessment of colony formation. The hypoxic preincubation of both cells caused an increase in survival following doxorubicin exposure. This was eight-fold for PC-3 cells and up to 12-fold for the TRAMP-C2 cells. Coincubation of the PC-3 cells with GTN resulted in complete inhibition of the hypoxia-induced resistance to chemotherapy. These results demonstrate that exogenous administration of GTN might be considered as a chemosensitising agent in prostate cancer.
Induction by chronic androgen deprivation of a hypoxia response in androgen-sensitive prostate cancer cells has been studied by a group from the US (Dr Aristotelis Anastasiadis, USA). Androgen deprivation induces apoptosis of prostate cells via suppression of blood flow and hence oxygen supply to these cells. It was postulated that androgen resistance might result from the activation of a hypoxia-response survival mechanism that protects cells from the deleterious effects of hypoxia. LNCaP cells were cultured in charcoal-stripped serum with and without androgen supplementation and cultures analysed at intervals for proteins and expression of HIF-1a transcription factor, VEGF, Akt and Forkhead and their phosphorylated forms and b-actin. Results indicate that androgen deprivation of the cells caused upregulation of VEGF expression, leading to increased angiogenic potential. The Akt-regulated apoptotic resistance mechanism was also stimulated. These findings confirm the involvement of the hypoxia-response pathway in cells subjected to a chronic androgen deprivation environment.
It has been proposed that common polymorphic variants of certain genes, such as the androgen and vitamin D receptor, could contribute to the development of prostate cancer. Single-nucleotide polymorphic variants in the 3UTR of p21cip1 and in codon 109 of p27kip1 were studied for an association with advanced prostate cancer (Dr Adam Kibel, USA). Genomic DNA from 96 patients with advanced prostate cancer and 106 cancerfree controls was isolated and p21cip1 and p27kip1 genotypes determined using polymerase chain reaction (PCR) amplification. The p21cip1 variant changes a cytosine to a thymine; genotypes were defined as CC, CT or TT. The p27kip1 variant changes a thymine to a guanine, resulting in a valine to glycine change at codon 109; genotypes were defined as VV, VG or GG. p21cip1 genotypes CT and TT were associated with an increased risk of advanced prostate cancer compared with the CC genotype. The p27kip1 genotype VV was also associated with an increased risk of advanced prostate cancer. Both of the associations were stronger in patients with hormone-independent disease.
Polymorphisms of the androgen receptor have been studied with regard to the clinical diagnosis and prognosis of prostate cancer (Dr Göran Ahlgren, Sweden). Prostate biopsy tissue samples from 134 men were studied; prostate cancer was confirmed in 88 cases. Genotyping of the androgen receptor CAG and GGC repeats was performed using PCR amplification and direct sequencing. It was shown that the lengths of the CAG and GGC segments did not differ between the androgen receptors of men with or without prostate cancer. The GGC/CAG ratio had a significant inverse correlation with age at diagnosis of prostate cancer and a significant correlation with free testosterone level. Of 13 patients dying of prostate cancer during follow-up, a lower median GGC/CAG ratio was noted than in those who were still alive or who died from other causes. It was concluded that CAG and GGC polymorphism of the androgen receptor did not impact on the risk of developing prostate cancer. Men with lower GGC/CAG ratios (lower androgen receptor activity), however, do appear to have lower androgen levels and a later clinical onset of prostate cancer than those with higher ratios. What's hot in the prostate? M Gleave and CP Evans
Genomic DNA of familial (n ¼ 36) and early-onset prostate cancer patients (n ¼ 38) in a Finnish community was screened for mutations in the coding region of the AR gene (Dr Mika Matikainen, Finland). Single-strand conformation polymorphism analysis screening of the AR gene showed band shifts in 10 of the 74 (13.5%) earlyonset prostate cancer patients. A silent polymorphism Q211Q in exon 1 was found in two (5.3%) early-onset patients and seven patients (19.4%) from the familial cancer group. One R726L substitution in exon 5 was identified in one prostate cancer family. It was concluded that androgen receptor gene mutations did not appear to influence genetic predisposition to prostate cancer.
A study was reported on the relationship between a T for C substitution in the human kallikrein-2 gene (KLK2) and circulating human kallikrein-2 (hK2) levels and the subsequent association with prostate cancer risk (Dr Robert Nam, Canada). The study involved 1287 men who had undergone prostate biopsy due to an elevated PSA (X4 ng/ml) or an abnormal digital rectal examination. Prostate cancer was identified in 661 men. Mutant and wild-type alleles were designated as the 'T' allele and the 'C' allele, respectively. The overall distribution of the CC, CT and TT KLK2 genotypes was 55.1, 38.2 and 6.8%, respectively. The corresponding median hK2 levels were 0.24, 0.18 and 0.062 ng/ml. The adjusted odds ratio (OR) for having prostate cancer for patients with the TT and CT genotype compared with patients with a CC genotype were 3.93 and 1.67, respectively. hK2 level also correlated with incidence of prostate cancer. It was concluded that the hK2 test may help select patients for repeat biopsy after an initial negative test.
A US study was reported suggesting a link between cigarette smoke and risk of prostate cancer (Dr David Penson, USA). A total of 753 men diagnosed with prostate cancer between 1993 and 1996 were included in the study together with 703 age-matched controls without prostate cancer from the same region. Statistical analysis indicated that current smokers had an increased risk (OR 1.4) compared with nonsmokers. A doseresponse relationship was noted between number of pack-years smoked and prostate cancer risk (trend, P ¼ 0.03). For men with a X40 pack-years of smoking, the OR was 1.6. Cessation of smoking was associated with a decrease in OR. This moderate increase in the risk of prostate cancer from smoking has health implications, particularly as stopping smoking appears to reduce that risk.
Drg-1 gene suppresses tumour metastasis in prostate cancer
Bandyopadhyay and co-workers (Cancer Res 2003; 63(8) : 1731-1736) report on the functional role of the Drg-1 gene in patients with metastatic and localised prostate cancer. Drg-1 is upregulated by the induction of differentiation in a colon carcinoma cell line. It is also regulated by several factors including hypoxia, androgen, p53 and Nmyc. In the current study, there was a significant inverse correlation of expression of Drg-1 with Gleason grade and overall survival. Gene expression in patients with lymph node or bone metastasis was significantly reduced compared with those with localised prostate cancer. A spontaneous metastasis assay in a severe combined immunodeficient (SCID) mouse model showed that Drg-1 almost completely inhibited lung colonisation of highly metastatic prostate cancer cells without affecting the growth of the primary tumours. The authors conclude that Drg-1 is potentially a candidate metastasis suppressor gene for prostate cancer and may serve as a useful prognostic marker.
Androgen-independent growth of LNCaP is mediated by GOF mutant p53
A report by Nesslinger et al (Cancer Res 2003; 63(9): 2228 -2233 indicates that gain-of-function (GOF) p53 mutants confer androgen-independent growth of LNCaP cells without the involvement of Akt and Bcl-2. Five stably transfected LNCaP cell lines were developed: four containing GOF mutant p53 alleles (G245S, R248W, R273H and R273C) and one containing a non-GOF p53 mutant allele (P151S). The four GOF p53 sublines were able to grow under androgen-depleted conditions, whereas the LNCaP parental line, vector-only line, and the non-GOF line were unable to grow. Androgen ablation caused the levels of the androgen receptor to decrease in the four GOF p53 sublines compared with the control lines. Decreased expression was accompanied by attenuated receptor activity. An increase in phosphorylated Akt levels was observed in both the GOF p53 sublines and the control lines. Bcl-2 remained unchanged or showed reduced expression in all of the cell lines in the absence of androgen compared with the presence of androgen.
Cooperation of two mutant p53 alleles contributes to Fas resistance
Contributions to the malignant phenotype are made through inactivation of p53 function and loss of sensitivity to Fas. In the majority of cases, only one of the p53 alleles is mutated, although some tumours acquire mutations in both alleles. Gurova et al (Cancer Res 2003; 63(11): 2905 -2912 have examined the biological significance of this phenomenon by analysing two p53 mutants, p53(223Leu) and p53(274Phe), from the Fasresistant prostate carcinoma cell line DU145. Both mutants differed from wild-type p53 in their conformation, transactivation ability and effect on the growth of p53-deficient cells, with p53(223Leu) being more similar to wild-type p53 than was p53(274Phe). Of note, coexpression of the DU145-derived mutants was dramatically different in terms of biological effect from that of each mutant expressed alone. Each mutant neutralised the others' growth-suppressive effects, but were not dominant-negative against wild-type p53. In combination, they were also capable of downregulating Fas expression and converting Fas-sensitive prostate carcinoma cells PC3 into Fas-resistant ones. The authors conclude that these findings indicate that two different p53 mutants can cooperate to generate a p53 protein with anti-Fas function, although separately they are rather weak. The combination of the two is likely to provide additional selective advantages to the tumour.
